Published in PLoS One on April 29, 2011
STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci Transl Med (2015) 1.33
The determinants of tumour immunogenicity. Nat Rev Cancer (2012) 1.28
Annexin A2 heterotetramer: structure and function. Int J Mol Sci (2013) 1.17
Annexin A2 and S100A10 regulate human papillomavirus type 16 entry and intracellular trafficking in human keratinocytes. J Virol (2013) 1.08
To "grow" or "go": TMEM16A expression as a switch between tumor growth and metastasis in SCCHN. Clin Cancer Res (2014) 1.05
Annexin A2: its molecular regulation and cellular expression in cancer development. Dis Markers (2014) 0.99
MicroRNA-206 functions as a pleiotropic modulator of cell proliferation, invasion and lymphangiogenesis in pancreatic adenocarcinoma by targeting ANXA2 and KRAS genes. Oncogene (2014) 0.97
A preclinical murine model of hepatic metastases. J Vis Exp (2014) 0.95
Annexin A2 is a new antigenic target for pancreatic cancer immunotherapy. Oncoimmunology (2012) 0.95
Annexin A2 is regulated by ovarian cancer-peritoneal cell interactions and promotes metastasis. Oncotarget (2013) 0.94
Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models. J Hematol Oncol (2013) 0.91
Annexin A2 promotes the migration and invasion of human hepatocellular carcinoma cells in vitro by regulating the shedding of CD147-harboring microvesicles from tumor cells. PLoS One (2013) 0.91
Vaccines for pancreatic cancer. Cancer J (2012) 0.90
Up-regulated miR155 reverses the epithelial-mesenchymal transition induced by EGF and increases chemo-sensitivity to cisplatin in human Caski cervical cancer cells. PLoS One (2012) 0.90
Dynamic reciprocity: the role of annexin A2 in tissue integrity. J Cell Commun Signal (2014) 0.90
Clathrin mediates endocytosis of progastrin and activates MAPKs: role of cell surface annexin A2. Am J Physiol Gastrointest Liver Physiol (2012) 0.90
Annexin A2 silencing inhibits invasion, migration, and tumorigenic potential of hepatoma cells. World J Gastroenterol (2013) 0.89
Pancreatic cancer stroma: understanding biology leads to new therapeutic strategies. World J Gastroenterol (2014) 0.89
Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells. Cancer Immunol Res (2015) 0.89
Expression characteristics and diagnostic value of annexin A2 in hepatocellular carcinoma. World J Gastroenterol (2012) 0.88
Progastrin overexpression imparts tumorigenic/metastatic potential to embryonic epithelial cells: phenotypic differences between transformed and nontransformed stem cells. Int J Cancer (2012) 0.87
The biochemistry and regulation of S100A10: a multifunctional plasminogen receptor involved in oncogenesis. J Biomed Biotechnol (2012) 0.87
Cationic lipid guided short-hairpin RNA interference of annexin A2 attenuates tumor growth and metastasis in a mouse lung cancer stem cell model. J Control Release (2014) 0.86
Role of YAP and TAZ in pancreatic ductal adenocarcinoma and in stellate cells associated with cancer and chronic pancreatitis. Sci Rep (2015) 0.85
Targeting annexin A2 reduces tumorigenesis and therapeutic resistance of nasopharyngeal carcinoma. Oncotarget (2015) 0.85
Semaphorin 3D autocrine signaling mediates the metastatic role of annexin A2 in pancreatic cancer. Sci Signal (2015) 0.85
The role of quantitative mass spectrometry in the discovery of pancreatic cancer biomarkers for translational science. J Transl Med (2014) 0.84
Three are better than one: plasminogen receptors as cancer theranostic targets. Exp Hematol Oncol (2013) 0.84
Identification of novel interaction between annexin A2 and keratin 17: evidence for reciprocal regulation. J Biol Chem (2012) 0.84
Prediction of functional phosphorylation sites by incorporating evolutionary information. Protein Cell (2012) 0.84
Tyrosine 23 Phosphorylation of Annexin A2 Promotes Proliferation, Invasion, and Stat3 Phosphorylation in the Nucleus of Human Breast Cancer SK-BR-3 Cells. Cancer Biol Med (2012) 0.83
Anxa2 binds to STAT3 and promotes epithelial to mesenchymal transition in breast cancer cells. Oncotarget (2015) 0.83
Current progress in immunotherapy for pancreatic cancer. Cancer Lett (2015) 0.83
Overexpression of annexin A2 is associated with abnormal ubiquitination in breast cancer. Genomics Proteomics Bioinformatics (2012) 0.82
PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition. J Pathol (2014) 0.82
Intracellular annexin A2 regulates NF-κB signaling by binding to the p50 subunit: implications for gemcitabine resistance in pancreatic cancer. Cell Death Dis (2015) 0.81
From plasminogen to plasmin: role of plasminogen receptors in human cancer. Int J Mol Sci (2014) 0.80
Decidual-secreted factors alter invasive trophoblast membrane and secreted proteins implying a role for decidual cell regulation of placentation. PLoS One (2012) 0.79
A novel mechanism for cancer cells to evade immune attack by NK cells: The interaction between NKp44 and proliferating cell nuclear antigen. Oncoimmunology (2012) 0.79
Specificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancer. Semin Oncol (2014) 0.79
Using Quantitative Seroproteomics to Identify Antibody Biomarkers in Pancreatic Cancer. Cancer Immunol Res (2016) 0.79
Reactive oxygen species exert opposite effects on Tyr23 phosphorylation of the nuclear and cortical pools of annexin A2. J Cell Sci (2015) 0.78
Domains I and IV of annexin A2 affect the formation and integrity of in vitro capillary-like networks. PLoS One (2013) 0.78
Inhibition of Annexin A2 gene transcription is a promising molecular target for hepatoma cell proliferation and metastasis. Oncol Lett (2013) 0.78
Expression and significance of annexin A2 in patients with gastric adenocarcinoma and the association with E-cadherin. Exp Ther Med (2015) 0.78
Cancer-Associated Fibroblasts in Pancreatic Cancer Are Reprogrammed by Tumor-Induced Alterations in Genomic DNA Methylation. Cancer Res (2016) 0.77
Next-generation cancer vaccine approaches: integrating lessons learned from current successes with promising biotechnologic advances. J Natl Compr Canc Netw (2013) 0.77
Annexin 2A sustains glioblastoma cell dissemination and proliferation. Oncotarget (2016) 0.75
Identification of serologic biomarkers for predicting microvascular invasion in hepatocellular carcinoma. Oncotarget (2016) 0.75
Heterogeneous stromal signaling within the tumor microenvironment controls the metastasis of pancreatic cancer. Cancer Res (2016) 0.75
Extracellular vesicles released from cells exposed to reactive oxygen species increase annexin A2 expression and survival of target cells exposed to the same conditions. Commun Integr Biol (2016) 0.75
Whole-Cell Cancer Vaccines Induce Large Antibody Responses to Carbohydrates and Glycoproteins. Cell Chem Biol (2016) 0.75
Unconventional Transport Routes of Soluble and Membrane Proteins and Their Role in Developmental Biology. Int J Mol Sci (2017) 0.75
Rack1 Mediates the Interaction of P-Glycoprotein with Anxa2 and Regulates Migration and Invasion of Multidrug-Resistant Breast Cancer Cells. Int J Mol Sci (2016) 0.75
Role of Annexin A2 in the EGF-induced epithelial-mesenchymal transition in human CaSki cells. Oncol Lett (2016) 0.75
FNDC3B promotes cell migration and tumor metastasis in hepatocellular carcinoma. Oncotarget (2016) 0.75
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell (2008) 14.80
Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res (2007) 5.12
Nuclear location of the putative transforming protein of avian myelocytomatosis virus. Cell (1982) 3.51
Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med (2004) 3.39
Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol (2001) 3.27
Annexins--unique membrane binding proteins with diverse functions. J Cell Sci (2004) 2.74
Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res (2008) 2.67
Mesothelin targeted cancer immunotherapy. Eur J Cancer (2007) 2.54
Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J Sci Am (1998) 2.03
Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Res (1980) 1.97
HEC, a novel nuclear protein rich in leucine heptad repeats specifically involved in mitosis. Mol Cell Biol (1997) 1.90
An annexin 2 phosphorylation switch mediates p11-dependent translocation of annexin 2 to the cell surface. J Biol Chem (2004) 1.68
Annexin 2 has an essential role in actin-based macropinocytic rocketing. Curr Biol (2001) 1.60
The role of annexin II in angiogenesis and tumor progression: a potential therapeutic target. Curr Pharm Des (2007) 1.57
Loss of type III transforming growth factor beta receptor expression increases motility and invasiveness associated with epithelial to mesenchymal transition during pancreatic cancer progression. Carcinogenesis (2007) 1.51
Annexin II: a plasminogen-plasminogen activator co-receptor. Front Biosci (2002) 1.47
Inhibition of STAT3 Tyr705 phosphorylation by Smad4 suppresses transforming growth factor beta-mediated invasion and metastasis in pancreatic cancer cells. Cancer Res (2008) 1.42
Tenascin C and annexin II expression in the process of pancreatic carcinogenesis. J Pathol (2006) 1.41
Pancreatic cancer: from molecular pathogenesis to targeted therapy. Cancer Metastasis Rev (2008) 1.38
Annexin A2 binding to endosomes and functions in endosomal transport are regulated by tyrosine 23 phosphorylation. J Biol Chem (2008) 1.36
Tyrosine phosphorylation of annexin A2 regulates Rho-mediated actin rearrangement and cell adhesion. J Cell Sci (2008) 1.30
S100A10, annexin A2, and annexin a2 heterotetramer as candidate plasminogen receptors. Front Biosci (2005) 1.29
Selective targeting of antitumor immune responses with engineered live-attenuated Listeria monocytogenes. Cancer Res (2006) 1.25
Progress in cancer genetics: lessons from pancreatic cancer. Ann Oncol (1999) 1.22
Annexin A2 phosphorylation mediates cell scattering and branching morphogenesis via cofilin Activation. Mol Cell Biol (2007) 1.21
Synergistic effect of a granulocyte-macrophage colony-stimulating factor-transduced tumor vaccine and systemic interleukin-2 in the treatment of murine colorectal cancer hepatic metastases. Ann Surg Oncol (2003) 1.18
Anti-annexin II antibodies in systemic autoimmune diseases and antiphospholipid syndrome. J Clin Immunol (2008) 1.13
Lentivirus-mediated gene transfer and expression in established human tumor antigen-specific cytotoxic T cells and primary unstimulated T cells. Hum Gene Ther (2003) 1.09
Pancreatic cancer: progress in cancer therapy. Crit Rev Oncol Hematol (2008) 1.04
Novel agents for the treatment of adenocarcinoma of the pancreas. Expert Rev Anticancer Ther (2009) 1.02
S100A6 binds to annexin 2 in pancreatic cancer cells and promotes pancreatic cancer cell motility. Br J Cancer (2009) 1.01
Annexin II overexpression predicts rapid recurrence after surgery in pancreatic cancer patients undergoing gemcitabine-adjuvant chemotherapy. Ann Surg Oncol (2008) 1.00
Secretion of Annexin II via activation of insulin receptor and insulin-like growth factor receptor. J Biol Chem (2002) 0.92
A novel model system for studying the double-edged roles of nitric oxide production in pancreatic cancer growth and metastasis. Oncogene (2003) 0.90
Annexin II-mediated plasmin generation activates TGF-beta3 during epithelial-mesenchymal transformation in the developing avian heart. Dev Biol (2004) 0.90
A modified invasion-3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide assay for quantitating tumor cell invasion. Cancer Res (1994) 0.87
S-100 protein binds to annexin II and p11, the heavy and light chains of calpactin I. Biochim Biophys Acta (1992) 0.87
Interferon-gamma reduces cell surface expression of annexin 2 and suppresses the invasive capacity of prostate cancer cells. J Biol Chem (2008) 0.85
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med (2013) 16.24
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell (2003) 15.43
Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell (2007) 14.58
c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature (2009) 13.28
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 13.12
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell (2007) 13.04
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (2011) 10.26
EMT and dissemination precede pancreatic tumor formation. Cell (2012) 9.27
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature (2003) 8.14
Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science (2009) 7.39
Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature (2004) 6.82
DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol (2009) 6.43
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol (2011) 6.16
An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res (2006) 5.52
Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell (2003) 5.36
Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res (2007) 5.12
Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med (2011) 5.03
Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U S A (2010) 4.97
Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res (2006) 4.83
An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol (2004) 4.74
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet (2012) 4.70
Expression of Yes-associated protein in common solid tumors. Hum Pathol (2008) 4.61
Altered telomeres in tumors with ATRX and DAXX mutations. Science (2011) 4.60
The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell (2010) 4.47
Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet (2011) 4.38
Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev (2012) 4.19
Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res (2012) 3.68
Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat (2011) 3.63
Guidelines for the next 10 years of proteomics. Proteomics (2006) 3.61
Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci U S A (2011) 3.51
Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice. Proc Natl Acad Sci U S A (2008) 3.43
Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol (2003) 3.40
Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med (2004) 3.39
Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy. Cancer Biol Ther (2005) 3.28
NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw (2009) 3.25
Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res (2003) 3.23
Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med (2005) 3.22
Evaluating the impact of a single-day multidisciplinary clinic on the management of pancreatic cancer. Ann Surg Oncol (2008) 3.14
Major histocompatibility complex class II-restricted presentation of a cytosolic antigen by autophagy. Eur J Immunol (2003) 3.12
Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst (2010) 3.08
The Hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program. Genes Dev (2010) 3.02
Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Pathol (2006) 3.01
Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. J Nanobiotechnology (2007) 2.93
Human embryonic stem cells have a unique epigenetic signature. Genome Res (2006) 2.89
Clinical proteomics: A need to define the field and to begin to set adequate standards. Proteomics Clin Appl (2007) 2.84
Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother (2013) 2.80
Evolutionary dynamics of cancer in response to targeted combination therapy. Elife (2013) 2.76
Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol (2009) 2.75
Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology (2012) 2.74
Hedgehog signaling is required for effective regeneration of exocrine pancreas. Gastroenterology (2008) 2.71
A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin Cancer Res (2007) 2.71
Circulating transforming growth factor-beta in Marfan syndrome. Circulation (2009) 2.69
Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol Cell Proteomics (2005) 2.66
Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of Hedgehog signaling on pancreatic ductal epithelial cells. Cancer Res (2005) 2.64
A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol Cancer Ther (2009) 2.61
Pancreatic carcinogenesis. Pancreatology (2008) 2.60
Tumor-initiating cells are rare in many human tumors. Cell Stem Cell (2010) 2.54
Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res (2003) 2.49
Laparoscopic distal pancreatectomy is associated with significantly less overall morbidity compared to the open technique: a systematic review and meta-analysis. Ann Surg (2012) 2.48
SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res (2009) 2.44
Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol (2002) 2.44
Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol (2011) 2.41
Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. Genes Dev (2010) 2.37
Array-based comparative genomic hybridization identifies localized DNA amplifications and homozygous deletions in pancreatic cancer. Neoplasia (2005) 2.35
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Patient readmission and mortality after colorectal surgery for colon cancer: impact of length of stay relative to other clinical factors. J Am Coll Surg (2012) 2.29
Cytoprotective role of Ca2+- activated K+ channels in the cardiac inner mitochondrial membrane. Science (2002) 2.23
MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology (2009) 2.23
Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am J Pathol (2002) 2.22
Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther (2010) 2.21
An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Mol Cancer Ther (2008) 2.21
Proteomic analysis of pharmacological preconditioning: novel protein targets converge to mitochondrial metabolism pathways. Circ Res (2006) 2.20
Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. Clin Cancer Res (2006) 2.13
Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol (2010) 2.12
miRNA biomarkers in cyst fluid augment the diagnosis and management of pancreatic cysts. Clin Cancer Res (2012) 2.10
Uromodulin levels associate with a common UMOD variant and risk for incident CKD. J Am Soc Nephrol (2009) 2.10
Copy number alterations in pancreatic cancer identify recurrent PAK4 amplification. Cancer Biol Ther (2008) 2.09